Temporal Improvement of a COVID-19-Positive Crohn's Disease Patient Treated With Bismuth Subsalicylate

by Wolf, Douglas C., Wolf, Christine H., Rubin, David T.
Published in Am J Gastroenterol (2020)

Predicting Outcomes and Tailoring Therapy in the Diagnosis and Treatment of IBD

by Scherl, Ellen J., Seidman, Ernest G., Wolf, Douglas C.
Published 2007

Community Perspectives: Combining Serology, Genetics, and Inflammation Markers for the Diagnosis of IBD and Differentiation Between CD and UC

by Wolf, Douglas C., Abraham, Bincy P., Afzali, Anita, Allegretti, Paul D., Arai, Ronen
Published 2012

Transcriptional Modulation of the ERK1/2 MAPK and NF-κB Pathways in Human Urothelial Cells After Trivalent Arsenical Exposure: Implications for Urinary Bladder Cancer

by Bailey, Kathryn A., Wallace, Kathleen, Smeester, Lisa, Thai, Sheau-Fung, Wolf, Douglas C., Edwards, Stephen W., Fry, Rebecca C.
Published 2012

Identification and Characterization of Adverse Effects in 21(st) Century Toxicology

by Keller, Douglas A., Juberg, Daland R., Catlin, Natasha, Farland, William H., Hess, Frederick G., Wolf, Douglas C., Doerrer, Nancy G.
Published 2012

Adherence rates and health care costs in Crohn’s disease patients receiving certolizumab pegol with and without home health nurse assistance: results from a retrospective analysis...

by Wolf, Douglas C, Jaganathan, Srihari, Burudpakdee, Chakkarin, Seetasith, Arpamas, Low, Robert, Lee, Edward, Gucky, Jay, Yassine, Mohamed, Schwartz, David A
Published in Patient Prefer Adherence (2018)

Effects of Prenatal Exposure to a Low Dose Atrazine Metabolite Mixture on Pubertal Timing and Prostate Development of Male Long Evans Rats

by Stanko, Jason P., Enoch, Rolondo R., Rayner, Jennifer L., Davis, Christine C., Wolf, Douglas C., Malarkey, David E., Fenton, Suzanne E.
Published 2010

Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn’s Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE...

by Panaccione, Remo, Sandborn, William J, D’Haens, Geert, Wolf, Douglas C, Berg, Sofie, Maa, Jen-fue, Petersson, Joel, Robinson, Anne M
Published in J Crohns Colitis (2018)

Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice

by Vande Casteele, Niels, Feagan, Brian G, Wolf, Douglas C, Pop, Anca, Yassine, Mohamed, Horst, Sara N, Ritter, Timothy E, Sandborn, William J
Published in Inflamm Bowel Dis (2020)

Placental Transfer of Anti-Tumor Necrosis Factor Agents in Pregnant Patients with Inflammatory Bowel Disease

by Mahadevan, Uma, Wolf, Douglas C., Dubinsky, Marla, Cortot, Antoine, Lee, Scott D., Siegel, Corey A., Ullman, Thomas, Glover, Sarah, Valentine, John F., Rubin, David T., Miller, Jocelyn, Abreu, Maria T.
Published 2012

A predictive data-driven framework for endocrine prioritization: a triazole fungicide case study

by Paul Friedman, Katie, Papineni, Sabitha, Marty, M. Sue, Yi, Kun Don, Goetz, Amber K., Rasoulpour, Reza J., Kwiatkowski, Pat, Wolf, Douglas C., Blacker, Ann M., Peffer, Richard C.
Published in Crit Rev Toxicol (2016)

Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study

by Sandborn, William J, Feagan, Brian G, Hanauer, Stephen, Vermeire, Severine, Ghosh, Subrata, Liu, Wenzhong J, Petersen, AnnKatrin, Charles, Lorna, Huang, Vivian, Usiskin, Keith, Wolf, Douglas C, D’Haens, Geert
Published in J Crohns Colitis (2021)

Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3

by Colombel, Jean-Frederic, Sandborn, William J, Ghosh, Subrata, Wolf, Douglas C, Panaccione, Remo, Feagan, Brian, Reinisch, Walter, Robinson, Anne M, Lazar, Andreas, Kron, Martina, Huang, Bidan, Skup, Martha, Thakkar, Roopal B
Published in Am J Gastroenterol (2014)

Illustrative case using the RISK21 roadmap and matrix: prioritization for evaluation of chemicals found in drinking water

by Wolf, Douglas C., Bachman, Ammie, Barrett, Gordon, Bellin, Cheryl, Goodman, Jay I., Jensen, Elke, Moretto, Angelo, McMullin, Tami, Pastoor, Timothy P., Schoeny, Rita, Slezak, Brian, Wend, Korinna, Embry, Michelle R.
Published in Crit Rev Toxicol (2016)

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

by Feagan, Brian G, Schreiber, Stefan, Wolf, Douglas C, Axler, Jeffrey L, Kaviya, Arpeat, James, Alexandra, Curtis, Rebecca I, Geransar, Parnia, Stallmach, Andreas, Ehehalt, Robert, Bokemeyer, Bernd, Khalid, Javaria Mona, O’Byrne, Sharon
Published in Inflamm Bowel Dis (2019)

Mode of action and human relevance analysis for nuclear receptor-mediated liver toxicity: A case study with phenobarbital as a model constitutive androstane receptor (CAR) activato...

by Elcombe, Clifford R., Peffer, Richard C., Wolf, Douglas C., Bailey, Jason, Bars, Remi, Bell, David, Cattley, Russell C., Ferguson, Stephen S., Geter, David, Goetz, Amber, Goodman, Jay I., Hester, Susan, Jacobs, Abigail, Omiecinski, Curtis J., Schoeny, Rita, Xie, Wen, Lake, Brian G.
Published 2013

Finfish and aquatic invertebrate pathology resources for now and the future

by Spitsbergen, Jan M., Blazer, Vicki S., Bowser, Paul R., Cheng, Keith C., Cooper, Keith R., Cooper, Timothy K., Frasca, Salvatore, Groman, David B., Harper, Claudia M., (Mac) Law, Jerry M., Marty, Gary D., Smolowitz, Roxanna M., Leger, Judy St., Wolf, Douglas C., Wolf, Jeffrey C.
Published 2008